Saturday 17 October 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
3.10
0.21
−6.34%
Follow CLNN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
387.20 | 428.39 | 289.36 | 289.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.47) | (12.68) | (12.06) | (15.54) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
431.06 | 506.01 | 331.12 | 326.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.34) | (3.75) | (3.57) | (3.75) | |
EV/FCF |
(5.32) | (3.75) | (3.56) | (3.75) | |
Quick Ratio |
2.00 | 0.88 | 0.48 | 0.95 | |
Current Ratio |
3.07 | 1.94 | 0.83 | 1.53 | |
Net Debt/EBITDA |
(1.73) | (6.10) | (1.17) | (1.49) | |
Debt/Assets |
79.47% | 75.42% | 74.68% | 70.75% | |
Debt/Equity |
(0.74) | (0.87) | (0.77) | (1.28) | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.19 | 0.56 | 0.52 | 0.45 | |
Capex/Depreciation |
0.00 | 0.00 | (0.08) | (0.03) | |
Interest Coverage |
(7.69) | (2.61) | (10.05) | (8.70) | |
Research and Development Expense of Revenue |
3,856.67% | 2,193.33% | 7,146.75% | 23,420.00% | |
Selling, General and Administrative Expense of Revenue |
2,144.44% | 11,646.67% | 2,657.14% | 14,333.33% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,155.56% | 8,746.67% | 1,772.73% | 11,353.33% | |
Graham Net Nets |
(0.43) | (0.48) | (0.46) | (0.35) | |
Graham Number |
12.55 | 10.78 | 10.22 | 9.57 | |
Earnings Yield |
(56.82%) | (64.91%) | (44.29%) | (56.22%) | |
Free Cash Flow Yield |
(20.91%) | (31.54%) | (32.12%) | (30.03%) | |
Revenue per Share |
0.01 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.21) | (0.39) | (0.49) | (0.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.39) | (0.49) | (0.39) | |
Cash per Share |
0.78 | 0.51 | 0.53 | 0.77 | |
Shareholders Equity per Share |
(2.00) | (1.62) | (1.78) | (1.20) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(2.00) | (1.62) | (1.78) | (1.20) | |
Free Cash Flow |
(2.59) | (4.53) | (4.83) | (4.00) | |
Working Capital |
10.06 | 6.29 | (1.80) | 4.37 | |
Capital Expenditures |
0.00 | — | (0.03) | (0.01) | |
Net Current Asset Value |
(32.90) | (27.45) | (26.75) | (21.99) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.36 | 0.73 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.05 | — | — | — | |
Average Payables |
0.99 | 1.36 | 1.07 | 1.52 | |
Average Inventory |
0.06 | 0.05 | 0.05 | 0.09 | |
Average Assets |
22.58 | 23.49 | 22.73 | 26.94 | |
Average Common Equity |
(16.66) | (11.89) | (13.22) | (8.24) |
Columns are period end dates